GELESIS HOLDINGS, INC.

Gelesis Holdings, Inc., trading under the ticker CPSR on the Nasdaq, is a biopharmaceutical and medical device company focused on weight management and metabolic health, best known for its FDA-cleared oral superabsorbent hydrogel treatment Plenity. The company reached public markets through a merger with Capstar Special Purpose Acquisition Corp, a blank-check vehicle that completed its IPO in 2021. The business combination closed in early 2022, and Gelesis filed its first post-merger annual report on Form 10-K with the SEC on April 1, 2022, marking its initial full reporting cycle as a publicly traded combined entity in the healthcare sector. Sign up at SpacDesk for complete filings, deal timelines, and sponsor data on Gelesis Holdings and hundreds of other SPAC transactions.